PIK3CA Mutation in HPV-Associated OPSCC Patients Receiving Deintensified Chemoradiation.

Autor:	Beaty BT; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, NC., Moon DH; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, NC.; University of North Carolina, Chapel Hill, NC.; Department of Medical Oncology, University of Tennessee, Memphis, TN., Shen CJ; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, NC., Amdur RJ; Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL., Weiss J; Department of Hematology/Oncology., Grilley-Olson J; Department of Hematology/Oncology., Patel S; Department of Hematology/Oncology., Zanation A; Department of Otolaryngology/Head and Neck Surgery., Hackman TG; Department of Otolaryngology/Head and Neck Surgery., Thorp B; Department of Otolaryngology/Head and Neck Surgery., Blumberg JM; Department of Otolaryngology/Head and Neck Surgery., Patel SN; Department of Otolaryngology/Head and Neck Surgery., Weissler MC; Department of Otolaryngology/Head and Neck Surgery., Yarbrough WG; Department of Otolaryngology/Head and Neck Surgery., Sheets NC; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, NC., Parker JS; Department of Genetics., Neil Hayes D, Weck KE; Department of Pathology., Ramkissoon LA; Department of Pathology., Mendenhall WM; Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL., Dagan R; University of Florida Health Proton Therapy Institute, Jacksonville, FL., Tan X; Department of Biostatistics., Gupta GP; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, NC., Chera BS; Department of Radiation Oncology, University of North Carolina Hospitals, Chapel Hill, NC.
Jazyk:	angličtina
Zdroj:	Journal of the National Cancer Institute [J Natl Cancer Inst] 2020 Aug 01; Vol. 112 (8), pp. 855-858.
DOI:	10.1093/jnci/djz224
Abstrakt:	PIK3CA is the most frequently mutated gene in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). Prognostic implications of such mutations remain unknown. We sought to elucidate the clinical significance of PIK3CA mutations in HPV-associated OPSCC patients treated with definitive chemoradiation (CRT). Seventy-seven patients with HPV-associated OPSCC were enrolled on two phase II clinical trials of deintensified CRT (60 Gy intensity-modulated radiotherapy with concurrent weekly cisplatin). Targeted next-generation sequencing was performed. Of the 77 patients, nine had disease recurrence (two regional, four distant, three regional and distant). Thirty-four patients had mutation(s) identified; 16 had PIK3CA mutations. Patients with wild-type-PIK3CA had statistically significantly higher 3-year disease-free survival than PIK3CA-mutant patients (93.4%, 95% confidence interval [CI] = 85.0% to 99.9% vs 68.8%, 95% CI = 26.7% to 89.8%; P = .004). On multivariate analysis, PIK3CA mutation was the only variable statistically significantly associated with disease recurrence (hazard ratio = 5.71, 95% CI = 1.53 to 21.3; P = .01). PIK3CA mutation is associated with worse disease-free survival in a prospective cohort of newly diagnosed HPV-associated OPSCC patients treated with deintensified CRT. (© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu